34TH
INTERNATIONAL AUSTRIANWINTER SYMPOSIUM
22 – 25 January 2020Zell am See | Salzburg, Austria
RADIONUCLIDES IN MOLECULAR IMAGING & THERAPY
FINAL PROGRAMME
3
Thursday, 23.1.2020
2
INVITATIONOn behalf of the Austrian Society of Nuclear Medicine & Molecular Imaging (OGNMB) and the Congress Committee we have the pleasure of inviting you to Zell am See, located in the heart of Austria.
The symposium is organized by the Austrian Society of Nuclear Medicine & Molecular Imaging (OGNMB). The 2020 meeting will be held under the auspices of our Congress President, Prof. Ora Israel from Haifa/Israel.Renown clinical and preclinical experts from various domains of Medicine, Radiopharmacy, Physics and experimental Nuclear Medicine are expected to join us for this International Symposium. Invited lectures will cover a broad range of topics in scientific, diagnostic and therapeutic applications of Nuclear Medicine, and be accompanied by free submissions from experts in the field. We would like to invite you to hear and discuss exciting interdisciplinary presentations as well as informative CME sessions and to meet with friends in an picturesque environment that stimulates your thoughts and creativity.
We look forward to welcoming you in Zell am See.
Welcome
Marcus Hacker, Vienna
President OGNMB
Ora Israel, Haifa
Scientific Chair
Alexander Becherer, Feldkirch
Congress Chair
CONGRESS ORGANISATION
Faculty
• Alexander Becherer, Feldkirch• Marcus Hacker, Vienna• Ora Israel, Haifa• Amir Kurtaran, Vienna• Markus Mitterhauser, Vienna• Armin Stegmayr, Innsbruck• Tatjana Traub-Weidinger, Vienna
GENERAL INFORMATION
Congress VenueFerry Porsche CONGRESS CENTERBrucker Bundesstraße 1a A - 5700 Zell am See +43 6542 474 75 0 +43 6542 474 75 75email: [email protected] URL: www.fpcc.at
Congress Organisation OGNMB HeadquarterSchmalzhofgasse 26 A – 1060 Vienna +43 1 890 44 27 +43 1 890 44 29 email: [email protected] URL: www.ognmb.at
WLANUser: OGNMBPassword: OGNMB2020
Congress LanguageEnglish
Congress Office
Wednesday 22 January 2020 09:00 – 19:00
Thursday 23 January 2020 07:30 – 18:00
Friday 24 January 2020 07:30 – 18:00
Saturday 25 January 2020 07:30 – 12:00
14 European CME Credits
The ‘Radionuclides in Molecular Imaging and Therapy - 34th International Austrian Winter Symposium”, January 22 – 25, 2020 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net
The event ‘Radionuclides in Molecular Imaging and Therapy - 34th International Austrian Winter Symposium” was granted 14 European CME credits. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme
54
6 7
Thursday, 23.1.2020Thursday, 23.1.2020
Mittwoch 22.1.2020
Stellenwert der Lungenszintigraphie aus Sicht des PulmologenO. Burghuber, Wien
10:00 – 10:30
Stellenwert der Lungenszintigraphie aus Sicht des NuklearmedizinersR. Lipp, Graz
10:30 – 11:00
Was sind die Erwartungen der Strahlentherapie an die Nuklearmedizin?F. Sedlmayer, Salzburg
11:00 – 11:30
Strahlentherapieplanung aus Sicht eines Medizinphysikers: Lagerung des Pat, Maske, Atemtriggerung, adaptive Bestrahlung im Laufe der StrahlentherapieU. Wolff, Wien
11:30 – 12:00
Mittagspause 12:00 – 13:00
Rechtsauskunft, Auskunftspflicht, Datenumgang, Befundübermittlung (per FAX, Email...) persönliche Versicherungspflicht für NuklearmedizinerI. Feil, Salzburg
13:00 – 13:30
PRÄ-KONGRESS SYMPOSIUM
Update Nuklearmedizinische Therapie: Status quo und Ausblick – Part 1: RadiojodtherapieC. Pirich, Salzburg
13:30 – 14:00
Update Nuklearmedizinische Therapie: Status quo und Ausblick – Part 2: Beyond RadiojodtherapieA. Haug, Wien
14:00 – 14:30
Kaffeepause 14:30 – 15:00
Nuklearmedizinische Fragestunde:
Beyond FDG PET/CT (SST, PSMA, Cholin, DOPA, FLT, FET, Amyloid)C. Uprimny, InnsbruckA. Kurtaran, WienS. Mirzaei, WienA. Becherer, Feldkirch
15:00 – 16:30
8 9
Thursday, 23.1.2020Thursday, 23.1.2020
WEDNESDAY, 22.1.2020
Opening Ceremony
Welcome Words O. Israel – Congress Chair M. Hacker – President OGNMB
The Zell Lecture - Medical Economics in Nuclear Medicine: Chances & ChallengesR. Zimmermann, Lalaye
19:00 – 20:30
Welcome Reception 20:30 – 22:00
SCIENTIFIC PROGRAMME
10 11
Thursday, 23.1.2020Thursday, 23.1.2020
THURSDAY 23.1.2020
Lunch Break 12:30 – 14:00Industry Lunch Symposium (more details on page 30)
Session 3 – Alternative Views on Radionuclide TherapyChairs: B. Gruy, Linz & H. Ahmadzadehfar, Bonn
Clinical Dosimetry and its impact on daily practice - interactive session with TEDW. Jentzen, EssenL. Freudenberg, Essen
Toxic SE of radionuclide therapyH. Ahmadzadehfar, Bonn
14:00 – 15:30
Coffee Break 15:30 – 16:00
Session 1 – The Brain as StarterChairs: T. Traub-Weidinger, Vienna & P. Meyer, Freiburg
The clinical need for molecular imaging in Neurology T. Berger, Vienna
The Nuclear Medicine view on Parkinson syndromes P. Meyer, Freiburg
Nuclear Medicine in differential diagnosis of dementiaP. Bartenstein, Munich
09:00 – 10:30
Coffee Break 10:30 – 11:00
Session 2 – The Scientific Chair Session The many faces of MSK hybrid imagingChairs: O. Israel, Haifa & M. Hacker, Vienna
IntroductionO. Israel, Haifa
The bone in cancer: more than a nice pictureZ. Keidar, Haifa
Benign condition: a zebra or a horse?P.A. Erba, Pisa
11:00 – 12:30
12 13
Thursday, 23.1.2020Thursday, 23.1.2020
Session 4 Chairs: M. Mitterhauser, Vienna & I. Virgolini, Innsbruck
211At-labelled poly-L-lysine based effector molecules for pretargeting applicationsSture Lindegren, Sweden
The influence of the application of furosemide combined with hydration on the occurence of halo artifact and on the intensity of tracer accumulation in the urinary bladder in [68Ga]Ga-PSMA-11 PET/CTSteffen Bayerschmidt, Austria
Comparison of two attenuation correction methods for semi-quantitative lymphoscintigraphy of the lower extremitiesAnna Zifko, Austria
[18F]FET and [18F]fluoro-choline PET/CT in primary diagnosis of low grade gliomaAnja Tea Golubić, Croatia
Multimodal in ovo imaging for PET-tracer development: a feasibility studyTheresa Balber, Austria
Synthesis of [68Ga]Ga-DOTA-NOC: First experiences with the simultaneous automated use of two Galli Ad GeneratorsElisabeth Plhak, Austria
16:00 – 17:00
Coffee Break 17:00 – 17:30
Session 5 – Fireside Conference – Future of Nuclear MedicineModerator: T. Beyer, Vienna & A. Becherer, Feldkirch, M. Gotthardt, Nijmegen
S. Mirzaei, ViennaP. Bartenstein, MunichA. Leisser, ViennaW. Schima, Vienna
17:30 – 18:30
THURSDAY 23.1.2020
14 15
Thursday, 23.1.2020Thursday, 23.1.2020
FRIDAY 24.1.2020
Session 6 – Nuclear Medicine in Breast Cancer ImagingChairs: C. Uprimny, Innsbruck & C. Xavier, Brussels
Imaging modalities in breast cancer: What do guidelines recommend?D. Egle, Innsbruck
The role of [18F]FDG-PET/CT in the diagnostic work-up of breast cancer patientsC. Uprimny, Innsbruck
Comparison of [18F]FDG-PET, [18F]NaF-PET and conventional bone scintigraphy in the evaluation of bone metastases in breast cancerM. Beheshti, Aachen
Molecular imaging of breast cancer, PET-tracers beyond [18F]FDG and [18F]NaFM. Keyaerts, Brussels
09:00 – 10:30
Coffee Break 10:30 – 11:00
Session 7 – Distinguished Pioneer LectureChairs: T. Beyer, Vienna & C. Decristoforo, Innsbruck
Beyond PET/MR: Multiparametric data integration in preclinical and translational researchB. Pichler, Tuebingen
11:00 – 11:30
Session 8 - Radiopharmaceutical aspects in the development of radio-immuno-targetingChairs: T. Beyer, Vienna & C. Decristoforo, Innsbruck
Radionuclide imaging of PD-L1 expression: from radiochemistry to clinical applicationS. Heskamp, Nijmegen
Radiolabeled anti-HER2 nanobody: a theranostic toolC. Xavier, Brussels
11:30 – 12:30
Lunch Break 12:30 – 14:00Industry Lunch Symposium (more details on page 30)
Session 9 - A Pick of Rocket Science in Nuclear Medicine Chairs: A. Haug, Vienna & S. Heskamp, Nijmegen
Deep learningL. Papp, Vienna
Beta cell imaging & bimodal tracersM. Gotthardt, Nijmegen
14:00 – 15:30
Coffee Break 15:30 – 16:00
16 17
Thursday, 23.1.2020Thursday, 23.1.2020
Session 10 – Guided Poster Tour Chairs: E. Guggenberg, Innsbruck & M. Beheshti, Aachen
Improved dosimetry for optimizing intraperitoneal targeted alpha therapy with 211AtStig Palm, Sweden
Feasibility of ultra low-dose thallium stress-redistribution protocol including stress prone imaging in obese patients using a CZT cameraMilan Kaminek, Czech Republic
Technical and economical evaluation of feasibility for implementing small cyclotron systems in Europe for cardiac pet with the tracer [13N]NH3.Klaas Pieter Koopmans, Netherlands
Modification of 68Ga-labelled siderophores for hybride imaging and theranosticsJoachim Pfister, Austria
Case report of a metastatic pheochromocytomaLisa-Maria Rossetti, Austria
Detection of cardiac transthyretin-related amyloidosis (ATTR) with bone scintigraphyAlexander Stephan Kroiss, Austria
Lenvatinib enhanced radioiodine uptake in a patient with low differentiated follicular thyroid cancer with distant metastases: a clinical case reportChristina Tugendsam, Austria
16:00 – 17:00 Serum calcitonin negative medullary thyroid carcinoma : a case ReportBrigitta Schmoll-Hauer, Austria
OGNMB General Assembly 17:00 – 18:30
FRIDAY 24.1.2020
18 19
Thursday, 23.1.2020Thursday, 23.1.2020
SATURDAY 25.1.2020
Breakfast Session by Industry 09:00 – 10:30(more details on page 30)
Session 11 – Medullary Thyoid Cancer- an Update (Joint Session OGNMB & OSDG)Chairs: S. Mirzaei, Vienna & R. Prommegger, Innsbruck
Pathological features of MTCO. Koperek, Vienna
Surgery of MTCC. Scheuba, Vienna
Peptide-based targeting strategies for diagnosis and therapy of MTCE. Guggenberg, Innsbruck
09:00 – 10:30
Coffee Break 10:30 – 11:00
Session 12 – Evergreen Nuclear CardiologyChairs: W. Schaefer, Moenchengladbach & M. Hacker, Vienna
Quantification of perfusion and function from MPS - state of the art 2020W. Schaefer, Moenchengladbach
Imaging infectious endocarditis and CIED infections: where we standP.A. Erba, Pisa
New opportunities in cardiac amyloidosis imaging and therapy: role of Nuclear MedicineR. Slart, Groningen
11:00 – 12:30
ClosingA. Becherer – Congress Chair OGNMBM. Hacker – President OGNMB
12:30 – 13:00
Farewell 13:00 – 14:00
20 21
Thursday, 23.1.2020Thursday, 23.1.2020
FREITAG 24. JÄNNER 2020
Begrüßung und offizielle Eröffnung 08:45 – 09:00
Session 1: PETVorsitz: A. Stegmayr, Innsbruck
Radioaktiv markierte Peptide zur Rezeptor-vermittelten Diagnostik und Therapie in der OnkologieE. Guggenberg, Innsbruck
09:00 – 09:30
Standards, Limitationen und Perspektiven der molekularen Bildgebung in der biologisch adaptiven PräzisionsstrahlentherapieM.Zeilinger, Wien
09:45 - 10:30
Pause 10:30 – 11:00Session 2: konv. NUK I Vorsitz: K. Artner, Wien
Somatostatinrezeptorszitigraphie im Rahmen der NET-TumoreCh. Farhan, Wien
11:00 - 11:45
Aufbau & Funktionsweise der D-Spect N. Irnstorfer, Wien
11:45 - 12:30
Mittagspause 12:30 – 14:00
Generalversammlung MTZV der OGNMB 14:00 – 14:30
Session 3: konv. NUK IIVorsitz: A. Gabriel-Werkl, Villach
J131-SD-ThearpieK. Artner, Wien
14:30 - 15:30
Pause 15:30 – 16:00Kritischer Umgang mit Gesundheits-AppsM. Kuprian, Innsbruck
16:00 – 17:00
RADIOLOGIETECHNOLOGIE-SYMPOSIUM 2020
Medizinisch-Technischer Zweigverein der Österreichischen Gesellschaft für Nuklearmedizin und Molekulare BildgebungZVR-Zahl: 513998998, Präsident: Stegmayr Armin, MHPE, T +43 512 5322 76772, [email protected], www.nukmtd.at
Termin: 24.-25. Jänner 2020, Ort: Zell am See (Ferry Porsche Kongresszentrum)Organisation: K. Artner, Wien; A. Gabriel-Werkl, Villach;
22 23
Thursday, 23.1.2020Thursday, 23.1.2020
SAMSTAG 25. JÄNNER 2020
Session 4: Forschung/Bacc.-arbeiten Vorsitz: Ch. Harris-Castellitz, WienPoster-Walk 09:00 - 09:30
Poster-Präsentationen 09:30 - 10:00
,,Ist Forschung ArztInnensache?”L. Hehenwarter, Salzburg
10:00 - 10:30
Pause 10:30 – 11:00Session 5: konv. Nuk III Vorsitz: U. Ofner, Graz
Der Einfluss der Akquisitionsparameter auf die Bildqualität einer 123I-FP-CIT SPECT M. Wochinz, Innsbruck
11:00 - 11:30
Eine neue Methode der Knochendichtemessung A.F. Hinterleitner, Steyr
11:30 - 12:00
Preisverleihung THP-Preis, DSD-Poster-Preis und Schlusswort
12:00 – 12:30
Farewell (Hauptkongress) 12:30 – 14:00
Mit der freundlichen Unterstützung folgender Firmen SPONSOREN des ZweigvereinsRADIOLOGIETECHNOLOGIE-SYMPOSIUM 2020
24
Thursday, 23.1.2020
BSM 6 x 3
Seibers-dorf 2 x 2
AAA 3,5 x 2
DSD 2,5 x 2
CATERING
CATERING
Elim
pex
2 x 2
Mediso
3 x 2
MiE GmbH 3 x 2
THP 6 x 3
Sanofi 4 x 2
TopMed Axeleris
2 x 2
IASON 3 x 2
Hermes 3 x 2
ABX 2 x 2
ITM 2 x 2
EISAI 2 x 2
RADIONUCLIDES IN MOLECULAR IMAGING AND THERAPY
34th International Austrian Winter Symposium
January 22-25, 2020
Merck 3 x 2
GE 3 x 2
Norg
ine
2 x 2
Sc
into
mics
– att
2
x 2
SIEMENS
5 x 3
Elysia Raytest
IBA 2 x 2
Pejcl Medizin- technik
RQS
2 x 2
CONGRESS CENTRE
.www.itm.ag
PRECISELY FOR ME.
Dedicated to giving cancer patients better answers than “maybe”.
190524_ITM_Az_210x297_RZ.indd 2 24.05.19 17:16
r
SOMAKIT TOC®
SPOT WHAT OTHERS MAY FAIL TO SEE
28 29
Thursday, 23.1.2020Thursday, 23.1.2020EXHIBITORS
ABX GmbH
ELYSIA RAYTEST
Hermes Medical Solutions
IASON GmbH
Gerhard Pejcl Medizintechnik GmbH
MiE GmbH
AAA – Advanced Accelerator Applications Germany GmbH - a Novartis Company
Axeleris Pharma GmbH
BSM Diagnostica
DSD Pharma GmbH
Eisai GesmbH
Norgine Pharma GmbH
RQS (Ruffani Quality Solutions)
sanofi-aventis GmbH
SCANNWORK medical imaging GmbH
Scintomics/ ATT GmbH
Siemens Healthineers
THP Medical Products Vertriebs GmbH
Seibersdorf Labor GmbH
TopMed Trade E.U.
GE Healthcare Handels GmbH
Elimpex
IBA
ITM Isotopen Technologien München AG
Mediso GmbH
Merck GmbHAXELERIS Pharma GmbH
30 31
Thursday, 23.1.2020Thursday, 23.1.2020CORPORATE MEMBERSINFORMATION LUNCH SYMPOSIUM INDUSTRY
THURSDAY 23. JANUARY 2020
Lunch Symposium by Norgine Targeted identification of Sentinel Lymph Nodes - Lymphoseek in theory and practiceM. HamböckM. Pau
12:30 – 13:30
FRIDAY 24. JANUARY 2020
Lunch Symposium by Advanced Accelerator Applications Germany GmbH
12:30 – 13:30
Beyond NETTER-1 – the evolving role of PRRT in the treatment of NET patientsR. Srirajaskanthan, London
SATURDAY 25. JANUARY 2020
Special Thyroidal Breakfast Session by DSD PharmaOptimizing Thyroxine Treatment: The Role of Softgel PreparationM. Centanni, Rom
08:30 – 09:00
Expanding precision medicine.
The healthcare market operates in a constant state of flux, which can be challenging as you strive for better clinical outcomes, faster work-flow, and consistent quality of results. What if you were able to visualize smaller lesions, get information for more accurate staging and patient risk stratification, and manage opera-tional inefficiencies to facilitate the most appro-priate treatment strategy1?
Accuracy to reveal the bigger picture. Performance to maximize efficiency.
Reproducibility to understand disease progression.
Learn more about Biograph Vision atsiemens.com/vision
1 Based on internal measurements (resolution and time of flight) compared to current systems. Data on file. Biograph Vision is not commercially available in all countries. Its future availability cannot be guaran-teed. Please contact your local Siemens Healthineers organization for further details.
Biograph Vision
See a whole new world of precision
Data
cou
rtes
y of
Cen
tre
Hosp
italie
r Uni
vers
itaire
Va
udoi
s, L
ausa
nne,
Sw
itzer
land
A91
MI-1
0477
-A2-
7600
3.2 mm LSO crystals1
Fast time of flight at 214 ps1
High effective sensitivity at 100 cps/kBq1
100% sensor coverage1
SIE-AUS-19-689_AZ_Biograph_Vision_A5_RZ.indd 1 04.12.19 14:48